search
Back to results

Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102

Primary Purpose

Obesity, Morbid Obesity

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
OMS102
Sponsored by
IntraPace, Inc
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring obesity, gastric stimulation, morbid obesity

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age of 18 - 60 years old at time of screening
  • BMI of 35 to 55 at time of screening
  • History of obesity ≥ 5 years
  • The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment
  • Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
  • No significant weight loss (< 5%) within four months prior to enrollment as documented in the subject's medical record.
  • Successful psychological evaluation following the institution psychological evaluation protocol for bariatric surgery or successful historic assessment performed no more than 6 months prior to enrollment.
  • Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more than 3 months prior to enrollment.
  • If taking anti-depressant medications, they must be stable for at least six months prior to enrollment
  • Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial
  • Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
  • Able to provide voluntary informed consent

Exclusion Criteria:

  • Any prior bariatric surgery
  • Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator)
  • Diagnosed with past or current psychiatric condition that may impair his/her ability to comply with the study procedures
  • Use of anti-psychotic medications
  • Diagnosed with a eating disorder such as bulimia or binge eating
  • Obesity due to an endocrinopathy (e.g. Cushing disease)
  • Insulin therapy
  • GI disease such as hiatal hernia (> 5cm), gastroparesis, esophageal motility disorders or intractable constipation.
  • Any history of peptic ulcer disease within 5 years prior to enrollment
  • History of Barrett's esophagus
  • Women who are pregnant, lactating or anticipate becoming pregnant within 24 months
  • Arthritis or other pathologies limiting physical activities that physician feels should exclude the patient from the study.
  • Cardiac history that physician feels should exclude the patient from the study.
  • Use of another investigational device or agent in the 30 days prior to enrollment
  • A history of life-threatening disease within 5 years prior to enrollment
  • Any other condition that, in the opinion of the investigator, would make the subject unsuitable for the study

Sites / Locations

  • Wolfart Klinik
  • Stadtkrankenhaus Schwabach
  • Chirurgische Klinik und Poliklinik I Zentrum für Operative Medizin

Outcomes

Primary Outcome Measures

Transgastric sensor site healing
Food sensor transgastric site healing will be evaluated during a gastro endoscopy exam performed three months after implant.

Secondary Outcome Measures

Excess weight loss
Percentage of excess body weight loss (%EWL) compared to baseline.
Safety Evaluation
Occurrence and severity of all adverse events
Quality of Life
Evaluation of the quality of life using the Moorehead-Ardelt II questionnaire
Eating Behavior
Eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ)
Comorbid Conditions
Any reduction of blood pressure and oral diabetes medications

Full Information

First Posted
February 22, 2012
Last Updated
February 27, 2012
Sponsor
IntraPace, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT01539850
Brief Title
Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102
Official Title
Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102. A Prospective Multicenter Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
April 2011 (Actual)
Study Completion Date
September 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IntraPace, Inc

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of this study is to evaluate the LGL102 implant safety in obese to morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight changes will be also evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Morbid Obesity
Keywords
obesity, gastric stimulation, morbid obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
OMS102
Other Intervention Name(s)
abiliti System
Intervention Description
Subjects will receive implanted OMS102 System.
Primary Outcome Measure Information:
Title
Transgastric sensor site healing
Description
Food sensor transgastric site healing will be evaluated during a gastro endoscopy exam performed three months after implant.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Excess weight loss
Description
Percentage of excess body weight loss (%EWL) compared to baseline.
Time Frame
3, 6, and 12 months
Title
Safety Evaluation
Description
Occurrence and severity of all adverse events
Time Frame
3, 6, and 12 months
Title
Quality of Life
Description
Evaluation of the quality of life using the Moorehead-Ardelt II questionnaire
Time Frame
3, 6 and 12 months
Title
Eating Behavior
Description
Eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ)
Time Frame
3, 6 and 12 months
Title
Comorbid Conditions
Description
Any reduction of blood pressure and oral diabetes medications
Time Frame
3, 6 and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of 18 - 60 years old at time of screening BMI of 35 to 55 at time of screening History of obesity ≥ 5 years The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods No significant weight loss (< 5%) within four months prior to enrollment as documented in the subject's medical record. Successful psychological evaluation following the institution psychological evaluation protocol for bariatric surgery or successful historic assessment performed no more than 6 months prior to enrollment. Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more than 3 months prior to enrollment. If taking anti-depressant medications, they must be stable for at least six months prior to enrollment Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial Able to provide voluntary informed consent Exclusion Criteria: Any prior bariatric surgery Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator) Diagnosed with past or current psychiatric condition that may impair his/her ability to comply with the study procedures Use of anti-psychotic medications Diagnosed with a eating disorder such as bulimia or binge eating Obesity due to an endocrinopathy (e.g. Cushing disease) Insulin therapy GI disease such as hiatal hernia (> 5cm), gastroparesis, esophageal motility disorders or intractable constipation. Any history of peptic ulcer disease within 5 years prior to enrollment History of Barrett's esophagus Women who are pregnant, lactating or anticipate becoming pregnant within 24 months Arthritis or other pathologies limiting physical activities that physician feels should exclude the patient from the study. Cardiac history that physician feels should exclude the patient from the study. Use of another investigational device or agent in the 30 days prior to enrollment A history of life-threatening disease within 5 years prior to enrollment Any other condition that, in the opinion of the investigator, would make the subject unsuitable for the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Horbach, MD
Organizational Affiliation
Stadtkrankenhaus Schwabach
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wolfart Klinik
City
Graefelfing
ZIP/Postal Code
92166
Country
Germany
Facility Name
Stadtkrankenhaus Schwabach
City
Schwabach
ZIP/Postal Code
91126
Country
Germany
Facility Name
Chirurgische Klinik und Poliklinik I Zentrum für Operative Medizin
City
Würzburg
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
25771794
Citation
Horbach T, Thalheimer A, Seyfried F, Eschenbacher F, Schuhmann P, Meyer G. abiliti Closed-Loop Gastric Electrical Stimulation System for Treatment of Obesity: Clinical Results with a 27-Month Follow-Up. Obes Surg. 2015 Oct;25(10):1779-87. doi: 10.1007/s11695-015-1620-z.
Results Reference
derived

Learn more about this trial

Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102

We'll reach out to this number within 24 hrs